Home » Medtronic Gets FDA OK for Overactive Bladder Treatment Study
Medtronic Gets FDA OK for Overactive Bladder Treatment Study
Medtronic Inc. (MDT) said it has begun the InSite Trial, a post-market study of its commercially available InterStim treatment for overactive bladder and urinary retention, after receiving approval from the Food and Drug Administration.
CNN
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May